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7 CURRENTOPINION Ablation of ischemic ventricular tachycardia:
evidence, techniques, results, and future directions Copyrig
0268-4705 Copyright  2015 WolteSamuel H. Baldinger, William G. Stevenson, and Roy M. JohnPurpose of review
This article summarizes current understanding of the arrhythmia substrate and effect of catheter ablation for
infarct-related ventricular tachycardia, focusing on recent findings.
Recent findings
Clinical studies support the use of catheter ablation earlier in the course of ischemic disease with moderate
success in reducing arrhythmia recurrence and shocks from implantable defibrillators, although mortality
remains unchanged. Ablation can be lifesaving for patients presenting with electrical storm. Advanced
mapping systems with image integration facilitate identification of potential substrate, and several different
approaches to manage hemodynamically unstable ventricular tachycardia have emerged. Novel ablation
techniques that allow deeper lesion formation are in development.
Summary
Catheter ablation is an important therapeutic option for preventing or reducing episodes of ventricular
tachycardia in patients with ischemic cardiomyopathy. Present technologies allow successful ablation in the
majority of patients, even when the arrhythmia is hemodynamically unstable. Failure of the procedure is
often because of anatomic challenges that will hopefully be addressed with technological progress.
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Infarct-related monomorphic ventricular tachycar-
dia typically arises from regions of poorly coupled
surviving myofibers within scar tissue characteristi-
cally showing slow electrical conduction. In ische-
mic cardiomyopathy, such arrhythmia substrates
are most commonly located subendocardially but
can also occur intramurally and subepicardially.
Areas of slow conduction can be large or widely
separated within scar tissue, giving rise to multiple
and potentially interconnected circuits that
can result in multiple ventricular tachycardia
morphologies. Progressive fibrosis and ventricular
remodeling can lead to onset of ventricular arrhyth-
mias late after myocardial infarction. A small pro-
portion (approximately 10%) of monomorphic
ventricular tachycardia in ischemic cardiomyop-
athy is because of automaticity or reentry involving
the Purkinje system.
The occurrence of sustained monomorphic
ventricular tachycardia is a marker for increased
mortality in patients with structural heart disease.
Implantable cardioverter defibrillators (ICDs) are
effective for prevention of sudden death, butht © 2015 Wolters Kluwe
rs Kluwer Health, Inc. All rights reserecurrent shocks reduce quality of life, cause post-
traumatic stress syndrome, and are associated with
worsened cardiac outcomes [1,2,3
&
]. Interrupting
areas of slow conduction by catheter ablation aims
to decrease the risk for ventricular tachycardia recur-
rence and thereby seeks to improve quality of life
and potentially reduce the risk of death. Ablation for
ventricular tachycardia storm (defined as three or
more episodes in 24h) or incessant ventricular
tachycardia can be lifesaving [4].
Effective ablation requires identification of the
ventricular tachycardia origin during mapping.
Ablation is typically performed during ventricular
tachycardia if hemodynamic stability can be main-
tained. If induced ventricular tachycardias are
unstable or the clinical ventricular tachycardiar Health, Inc. All rights reserved.
rved. www.co-cardiology.com
KEY POINTS
 Catheter ablation for sustained monomorphic
ventricular tachycardia associated with coronary artery
disease can significantly reduce ventricular tachycardia
recurrence and ICD shock burden for most patients.
 Advances in mapping and ablation technology coupled
with evolving techniques for substrate modification hold
promise for improved outcomes for ventricular
tachycardia ablation.
 Late ventricular tachycardia recurrence is common, and
the effect of ablation on overall mortality has not been
defined in prospective randomized clinical studies.
 Ablation should be considered earlier in the course of
ventricular tachycardia without waiting to exhaust all
pharmacological therapies but with due considerations
to risks and benefits.
Arrhythmiascannot be induced, ablation aims to modify the
arrhythmia substrate identified during stable sinus
or paced rhythms (substrate-guided ablation).
Recent studies have advanced both strategies. The
review will address the recent advances in tech-
niques, clinical experience, and outcomes for abla-
tion for monomorphic ventricular tachycardia in
ischemic cardiomyopathy. Polymorphic ventricular
tachycardia and ventricular fibrillation that occur
more often in the acute or subacute period of myo-
cardial ischemia or infarction are not discussed. Copyright © 2015 Wolters Kluwer 
Table 1. Indications for catheter ablation of ventricular tachycard
Catheter ablation of VT is recommended for
1 Patients with SMVT, including VT terminated by an ICD, that recur
are not tolerated or not desired
2 Control of incessant SMVT or VT storm that is not because of a tra
3 Patients with frequent PVCs, NSVTs, or VT that is presumed to cau
4 Bundle branch reentrant or interfascicular VTs
5 Recurrent sustained polymorphic VT and VF that is refractory to an
targeted for ablation
Catheter ablation should be considered for
1 Patients who have one or more episodes of SMVT despite therapy
2 Patients with recurrent SMVT because of prior MI who have LV eje
is an acceptable alternative to amiodarone therapy
3 Patients with hemodynamically tolerated SMVT due to prior MI wh
they have not failed antiarrhythmic drug therapy
VT catheter ablation is contraindicated
1 In the presence of a mobile ventricular thrombus (epicardial ablati
2 For asymptomatic PVCs and/or NSVT that are not suspected of ca
3 When VT is because of transient, reversible causes, such as acute
ICD, implantable cardioverter defibrillator; LV, left ventricle; MI, myocardial infarctio
contractions; SMVT, symptomatic sustained monomorphic ventricular tachycardia; V
30 www.co-cardiology.comCURRENT EVIDENCE, RECENT
DEVELOPMENTS, AND ONGOING TRIALS
Indications and timing for postinfarct
ventricular tachycardia ablation
With increasing experience and expertise, catheter
ablations are being increasingly employed earlier in
the course of ventricular tachycardia without wait-
ing to exhaust all pharmacological options. Table 1
summarizes current recommendations for the use of
catheter ablation according to the 2009 European
Heart Rhythm Association/Heart Rhythm Society
(EHRA/HRS) Expert Consensus on Catheter Abla-
tion of Ventricular Arrhythmias [5].
Two randomized trials [ventricular tachycardia
ablation in coronary heart disease (VTACH) and
Substrate Mapping and Ablation in Sinus Rhythm
to Halt Ventricular Tachycardia (SMASH-VT)]
explored the use of catheter ablation in ICD recip-
ients with prior myocardial infarction, ventricular
tachycardia, and impaired left ventricular function
[6,7]. Both studies found a significant reduction in
ventricular tachycardia recurrence during follow-up
of approximately 2 years. However, neither of these
trials was sufficiently powered to examinemortality.
In a retrospective study, Bunch et al. [8] reported a
lower risk of death and heart failure hospitalizations
in patients treatedwith ventricular tachycardia abla-
tion after an ICD shock compared with patients
managed medically only. Recent publications sup-
port an early invasive approach. In a single-center,Health, Inc. All rights reserved.
ia in patients with structural heart disease (adapted from [5])
s despite antiarrhythmic drug therapy or when antiarrhythmic drugs
nsient reversible cause
se ventricular dysfunction
tiarrhythmic therapy when there is a suspected trigger that can be
with one or more class I or III antiarrhythmic drugs
ction fraction >0.30 and expectation for 1 year of survival, and it
o have reasonably preserved LV ejection fraction (>0.35) even if
on may be considered)
using or contributing to ventricular dysfunction
ischemia, hyperkalemia, or drug-induced torsade de pointes
n; NSVT, nonsustained ventricular tachycardia; PVCs, premature ventricular
F, ventricular fibrillation; VT, ventricular tachycardia.
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Ablation of ischemic ventricular tachycardia Baldinger et al.observational study, Dinov et al. [9
&&
] reported better
acute and long-term success if catheter ablation of
scar-related ventricular tachycardia was performed
within 30 days after the first documented ventricu-
lar tachycardia. Once again, a mortality benefit was
not evident in patients who underwent early ven-
tricular tachycardia ablation compared with those
who had their ablation late (>1 year) after their first
presentation with ventricular tachycardia.
The benefits of early catheter ablation and its
superiority to medical therapy are the subject
of ongoing randomized trials. The PARTITA
trial (NCT01547208) is randomizing patients who
experience an appropriate ICD shock to immediate
catheter ablation orwaiting until the occurrence of a
ventricular tachycardia storm. The Substrate Tar-
geted Ablation Using the FlexAbilityTM Ablation
Catheter System for the Reduction of Ventricular
Tachycardia (STAR-VT) trial (NCT02130765) aims to
show a benefit of ventricular tachycardia ablation as
first line therapy compared with medical therapy in
patients with documented monomorphic ventricu-
lar tachycardia (either spontaneous or induced by
programmed stimulation) who have an implanted
ICD. The Ventricular Tachycardia (VT) Ablation
Versus Enhanced Drug Therapy (VANISH) trial
(NCT00905853) aims to compare aggressive antiar-
rhythmic therapy to catheter ablation for ventricu-
lar tachycardia recurrence after receiving ICD
therapy despite antiarrhythmic drugs.Mapping strategies and image integration
Electroanatomic mapping systems are routinely
used in most centers for voltage and activation
mapping and for navigation of catheters within
the cardiac chambers. Automated multipoint acqui-
sition from multipolar catheters permit fast, high-
resolution mapping to identify abnormal tissue that
typically demonstrates low voltages, fractionation,
and late potentials [10]. The judicious use of uni-
polar and bipolar voltage maps enables the identi-
fication of border zones. When combined with
analysis of electrograms and pacing maneuvers,
conducting channels that support reentry circuits
within scars can be identified during stable sinus or
paced rhythm [11,12].
Mapping systems also allow integration of real-
time intracardiac ultrasound images, fluoroscopy,
and previously acquired MRI or computer tomogra-
phy. Contrast enhanced MRI may be used to
identify ventricular tachycardia substrate and areas
that are likely to contain critical isthmus
sites [13,14]. Prospective studies are required to
assess whether such imaging guidance will improve
the efficiency and efficacy of ventricular tachycardia Copyright © 2015 Wolters Kluwe
0268-4705 Copyright  2015 Wolters Kluwer Health, Inc. All rights reseablation. Image integration is potentially useful to
minimize risks of phrenic nerve and coronary artery
injury during epicardial ventricular tachycardia
ablation [15]. MRI-guided interventions with intra-
procedural imaging may facilitate substrate identi-
fication, navigation, lesion formation, and early
detection of complications [16]. However, the
incorporation of anMRI scanner in the electrophysi-
ology laboratory is expensive and raises multiple
logistical issues.Contact force-sensing catheters
Radiofrequency ablation lesion creation is critically
dependent on adequate contact force between the
catheter and tissue [17]. Newer ablation catheters
incorporate contact force sensors [18]. In an ovine
model, contact force monitoring improved lesion
formation in the ventricles when ablating both from
the endocardium and the epicardium [19]. Contact
force monitoring during mapping increases speci-
ficity for identifying low-voltage area and abnormal
electrograms [20]. The clinical benefits of contact
force mapping and ablation for ventricular tachy-
cardia are yet to be fully elucidated.Substrate-based ablation
The critical isthmus of a specific monomorphic
ventricular tachycardia can be identified by acti-
vation or entrainment mapping during ventricular
tachycardia, if the ventricular tachycardia is hemo-
dynamically stable or can be induced and termi-
nated reproducibly to allow mapping during short
episodes [21–23]. In clinical practice, themajority of
induced ventricular tachycardias are hemodynami-
cally unstable and multiple morphologies of ven-
tricular tachycardia, often reflecting multiple
reentry circuits, are induced with repeated attempts
to initiate ventricular tachycardia. Therefore, abla-
tion is often limited to targeting the arrhythmia
substrate during sinus or paced rhythm. Areas of
slow conduction and late potentials within areas of
low voltage have been correlated with critical isth-
mus sites for reentry [24–26].
Based on these observations, several strategies
for modifying the ventricular tachycardia substrate
have been described recently (Table 2). These have
included the targeting of sites with late potentials or
fractionated electrograms that can be shown to be
poorly coupled to the surrounding myocardium
[27,28], circumferential ablation of the scar area
[29], circumferential core isolation around critical
ventricular tachycardia circuit elements [30], or
‘homogenization’ of the scar with extensive over-
lapping ablation lesions [31]. de Chillou et al. [32]r Health, Inc. All rights reserved.
rved. www.co-cardiology.com 31
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Arrhythmias
32 www.co-cardiology.comlocated the critical isthmus by pace-mapping in
sinus rhythm in a selected population with hemo-
dynamically stable ventricular tachycardia, and
Berruezo et al. [33] recently suggested that ‘dechan-
neling’ of the scar specifically targets channels
relevant to the ventricular tachycardia. These inves-
tigators targeted the earliest of all recorded ‘late’
potentials in the scar border zone during sinus
rhythm under the assumption that these areas
represent entrance sites of conduction channels.
Ablation at the entrance sites eliminated the con-
ducting channels, thereby limiting the total abla-
tions necessary for abolishing conducting channels
in the scar. Tung et al. demonstrated that local
ablation can modify electrical activity in scar
regions remote from the ablation site [34]. However,
the optimal strategy resulting in effective ablation
but at the same timeminimizing unnecessary radio-
frequency application and procedure time is still not
known. Anatomically ablating unexcitable scar
might not be necessary, and abnormal electrograms
may arise from tissue remote from the ablation
catheter [35].
At our center, substrate modification of the scar
is performed, targeting regions of slow conduction
evident as late or fractionated potentials.We aim for
sites where pace-mapping approximates the
morphology of an induced clinical ventricular
tachycardia and has a stimulus to QRS delay
>40ms (Fig. 1). Ablation is usually performed with
a contact-sensing catheter aiming for 10–20g of
contact force and impedance drop of 10–15V
during ablation. As an acute endpoint, we aim to
achieve noninducibility of all sustained monomor-
phic ventricular tachycardia by rendering the whole
scar or scar areas felt to be involved in ventricular
tachycardia circuits unexcitable to pacing (10mA at
2ms pulse width) or to disconnect them from
healthy myocardium.Hemodynamic support during ventricular
tachycardia ablation
Hemodynamic support using percutaneous left
ventricular assist devices (pLVADs) with an Impella
Recover 2.5 (Abiomed, Inc., Danvers, Massachu-
setts, USA), a TandemHeart device (Cardiac Assist,
Inc., Pittsburgh Pennsylvania, USA) or extracorpor-
eal membrane oxygenators may offer an alternative
for selected high-risk patients and may allow map-
ping of fast ventricular tachycardia in the setting of
poor ventricular function or significant coronary
artery disease.
Recent small retrospective series showed
that pLVAD support is feasible during ablation
[36–38]. Ventricular tachycardias could be mappedHealth, Inc. All rights reserved.
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Clinical VT
I
II
III
I
Pace-mapping within the scar
II
III
V1
V5
AbI prox
AbI dist
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
FIGURE 1. Example of an endocardial voltage map of the left ventricle that shows a large anteroseptal scar. Areas in purple
represent bipolar voltages of 1.5mV or greater. Blue, green, and yellow represent decreasing gradients of voltage, with red
representing areas with voltage less than 0.5mV. Late and fractionated electrograms are recorded from a multispline catheter
in the scar area (electrograms in green in the right panel of figure). Pacing shows a good match (bottom panel) to the clinical
VT (left panel) with a long stimulus-to-QRS interval, consistent with a slowly conducting channel. Blue dots represent areas
where late potentials were recorded and red dots represent points on ablation. Abl, ablation catheter; dist, distal; prox,
proximal; VT, ventricular tachycardia.
Ablation of ischemic ventricular tachycardia Baldinger et al.for relatively longer periods of time and were termi-
nated by radiofrequency ablation more often com-
pared with a control group without hemodynamic
support or with an intraaortic balloon pump. How-
ever, there was no difference in acute procedural
success or ventricular tachycardia recurrence rates
during follow-up. In addition, the magnetic motor
of the Impella system can interfere with the electro-
anatomic mapping, especially during mapping
in the ventricular outflow tracts. Extracorporeal
membrane oxygenation offers biventricular support
and does not interfere with the mapping systems.
Extracorporeal membrane oxygenation does not Copyright © 2015 Wolters Kluwe
0268-4705 Copyright  2015 Wolters Kluwer Health, Inc. All rights reseunload the left ventricle as compared with pLVAD
but offers better hemodynamic support (4–6 l/min).Epicardial ablation
When endocardial ablation fails, it is often because
of the location of critical components of a ventric-
ular tachycardia circuit deep in the myocardium or
in the subepicardium. Epicardial ablation has
become an essential component of ablation strat-
egies, especially for ventricular tachycardia because
of nonischemic cardiomyopathies, although prox-
imity of major coronary vessels or the phrenic nerver Health, Inc. All rights reserved.
rved. www.co-cardiology.com 33
Arrhythmiasto critical sites may preclude adequate ablation [39].
In ischemic heart disease, epicardial ablation is
usually performed after failed endocardial ablation.
An initial endo–epicardial approach might be
beneficial in selected patients. A recent small
single-center study showed an association between
an initial combined approach and less hospitaliz-
ation and reablation during follow-up, but failed to
show any differences in ventricular tachycardia
recurrence or mortality [40].Techniques for ablation of intramural
substrate
Although the advent of cooled tip radiofrequency
catheters and contact force monitoring has
improved lesion formation, safe delivery of deep
intramyocardial lesions remains a problem. Bipolar
radiofrequency energy between two separate abla-
tion catheters positioned on the septum from both
ventricles has proven to be beneficial in isolated
cases and in preliminary studies [41–43].
Transcoronary ethanol ablation is an approach
that is used in the setting of malignant refractory
ventricular tachycardia when standard approaches
fail [44]. Important considerations including coron-
ary anatomy, risk of heart block, and risk of hemo-
dynamic deterioration from the loss of functioning
myocardium.
Needle electrodes for the creation of deeper
intramural lesions show promise in early human
studies where conventional catheter ablation tech-
niques have been unsuccessful [45,46]. The use of a
warm saline-enhanced needle electrode where
radiofrequency energy is applied through the saline
stream into deep myocardial layers shows promise
in ablation of viable tissue in large myocardial
infarct scars [47].Procedural endpoints and outcome
Reported ventricular tachycardia recurrence rates
after postinfarct ventricular tachycardia ablation
procedures vary widely, but typically range between
30 and 50% in the larger studies. The most common
origin of recurrent ventricular tachycardia is from
areas adjacent to prior ablation lesions suggesting
that the ventricular tachycardia exit points may
have been altered by ablation [48].
The only endpoint criterion endorsed by current
guidelines is noninducibility of ventricular tachy-
cardia by programmed stimulation [5]. Absence of
inducible ventricular tachycardia has been associ-
atedwith better outcome [49], but has the limitation
of the probabilistic nature of ventricular tachyc
ardia inducibility. The predictive accuracy of Copyright © 2015 Wolters Kluwer 
34 www.co-cardiology.comprogrammed stimulation has also been disappoint-
ing [50]. Ventricular tachycardia recurrence has
been observed in 29%of patients whowere rendered
noninducible acutely [51]; this may reflect healing
and contraction of initial radiofrequency lesions
[52]. The various techniques of substrate-based abla-
tion described above have introduced additional
acute endpoints, such as elimination of all late or
abnormal electrograms [27,31,53]. Development of
more reliable endpoints for ventricular tachycardia
ablation procedures remains a high priority.
The impact of ventricular tachycardia ablation
on mortality is not well defined. A recent meta-
analysis found a lower mortality in patients in
whom ventricular tachycardia was rendered non-
inducible by programmed stimulation [49]. The
analysis, however, did not adjust for differences in
other risk predictors. A retrospective analysis per-
formed by Yokokawa et al. [54
&
] involving 1064
patients from seven centers suggested noninduci-
bility as an independent predictor of survival. The
study could not, however, evaluate the independent
impact of ventricular tachycardia recurrence on
mortality. A strong association between freedom
from ventricular tachycardia and transplant-free
survival during follow-up was demonstrated in a
retrospective multicenter study involving 2061
patients [55
&
], and patients with early ventricular
tachycardia recurrence, within seven days after abla-
tion, had a greater than two-fold increase in
mortality in one series [56].Complications of ventricular tachycardia
ablation
The most common complications are related to
vascular access and usually resolve spontaneously
[57]. Cardiac tamponade occurs in about 1% of
patients [58]. From a nationwide inpatient sample
database, Palaniswamy et al. [59] reported major
complication rates of 11.2% (including vascular:
6.9%, cardiac: 4.3%, and neurologic: 0.5%) and
in-hospital mortality rates (1.6%) in the United
States during 2002–2011. Most larger trials, how-
ever, reported lower complication rates [4,6,7], and
at our center, complications related to the ablation
are seen in about 5%. The majority of ablation-
related mortality is because of uncontrolled ventric-
ular arrhythmia and associated heart failure.Future directions
Incorporating pathophysiological considerations
beyond anatomic scar assessment in mapping of
ventricular tachycardia substrate may prove useful.
In a recent pilot study, Klein et al. [60
&
] described aHealth, Inc. All rights reserved.
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Ablation of ischemic ventricular tachycardia Baldinger et al.novel mapping approach for postinfarction ventric-
ular tachycardia ablation by integrating iodine-
123-labeled-metaiodobenzylguanidine scintigraphy
with voltage mapping, enabling identification of
viable but denervated myocardial tissue.
The quality and durability of ablation lesions
will continue to be a major determinant of clinical
outcome. Technology allowing the monitoring of
lesion size will continue to play an important role in
improving outcomes. Electroporation is a nonther-
mal ablation modality capable of creating deep
myocardial lesions. Animal studies have suggested
its potential application in epicardial ablation [61].CONCLUSION
Catheter ablation for ventricular tachycardia associ-
ated with ischemic cardiomyopathy can signifi-
cantly reduce ventricular tachycardia recurrences,
and this should translate into an improved quality
of life for patients who are having recurrent ven-
tricular tachycardia terminated by ICD shocks and
should be considered early in the management of
these patients. Complication rates are acceptable,
but recurrence rates remain significant. Technologi-
cal advances in mapping and ablation are expected
to further improve success rates.
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